Equitec Proprietary Markets, LLC Alaunos Therapeutics, Inc. Call Options Transaction History

Equitec Proprietary Markets, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Jan 31, 2022	SELL	$1.09 - $1.89 $4,687 - $8,127	-4,300 Reduced 22.63%	14,700 $16,000
Q3 2021 Oct 12, 2021	SELL	$1.44 - $2.73 $14,976 - $28,392	-10,400 Reduced 35.37%	19,000 $35,000
Q2 2021 Jul 20, 2021	SELL	$2.63 - $3.67 $23,933 - $33,397	-9,100 Reduced 23.64%	29,400 $78,000
Q4 2020 Jan 26, 2021	BUY	$2.09 - $3.09 $15,047 - $22,248	7,200 Added 23.0%	38,500 $97,000
Q3 2020 Oct 13, 2020	SELL	$2.39 - $3.43 $57,121 - $81,977	-23,900 Reduced 43.3%	31,300 $79,000
Q1 2020 Apr 19, 2021	BUY	$1.9 - $4.98 $42,750 - $112,050	22,500 Added 68.81%	55,200 $199,000
Q4 2018 Jan 30, 2019	BUY	$1.61 - $3.62 $19,964 - $44,888	12,400 Added 61.08%	32,700 $61,000
Q3 2018 Oct 15, 2018	SELL	$2.26 - $3.27 $4,971 - $7,194	-2,200 Reduced 9.78%	20,300 $65,000
Q2 2018 Jul 17, 2018	SELL	$3.02 - $4.94 $4,832 - $7,904	-1,600 Reduced 6.64%	22,500 $68,000
Q1 2018 May 23, 2018	SELL	$3.46 - $5.14 $31,140 - $46,260	-9,000 Reduced 27.19%	24,100 $94,000
Q4 2017 Jan 24, 2018	SELL	$4.0 - $6.54 $14,800 - $24,198	-3,700 Reduced 10.05%	33,100 $137,000
Q3 2017 Oct 23, 2017	BUY	$4.99 - $6.57 $183,632 - $241,776	36,800	36,800 $226,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $348M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Equitec Proprietary Markets, LLC, based on Form 13F filings with the SEC.

Stay updated on Equitec Proprietary Markets, LLC with notifications on news.